Specifically, in 2021-2023, Moderna invested proceeds from its pandemic-era vaccine sales into building a diverse pipeline and established the market for its COVID-19 vaccine, Spikevax®.
Specifically, in 2021-2023, Moderna invested proceeds from its pandemic-era vaccine sales into building a diverse pipeline and established the market for its COVID-19 vaccine, Spikevax®. In ...
Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Moderna said the Spikevax 2024-2025 formula is expected to be available across the U.S. in the days immediately following approval. Pfizer also said shipping will begin immediately. Thursday ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback